Introduction
Obesity has become one of the most significant risk factors for various 36 diseases. Because of the large number of overweight patients and the rapid increase in 37 obesity in recent years, obesity has been considered to be one of the major health 38 problems worldwide. Drug development to treat obesity has been widely studied, and 39 active compounds from plants can lead to anti-obesity medications. 1-3 40 For the development of new anti-obesity drugs, lipid catabolism has been 41 considered as an effective therapeutic target. 4 Lipolysis, a process to break down stored 42 lipids, is a critical aspect to diminish lipid amount. Hence, natural-derived compounds 43 that stimulate hydrolysis of triglyceride to glycerol and fatty acids are of great interest to 44 combat obesity. 45 In an effort to discover anti-obesity agents from medicinal plants, our research 46 group have uncovered the potential of Eurycoma longifolia Jack (family 47 6 88 purified by Toyopearl HW-40F (Tosoh Co., Tokyo, Japan) column chromatography (φ 89 15 mm × 160 mm) with water as the eluent. The active fraction was finally purified by 90 HPLC using an InertSustain C18 column (φ20×250 mm; GL Science Co., Tokyo, 91 Japan) with 20% aq. methanol as an eluent to obtain eurycomanone (1, 16.3 mg), 12,13 13 92 β,21-epoxyeurycomanone (2, 4.8 mg), 12,14 and 13β,21-dihydroxyeurycomanone (3, 3.6 93 mg). 9, 13 The water-soluble fraction (4.10 g) was similarly separated to obtain additional 94 1 (68.2 mg), 2 (14.0 mg), and 3 (8.6 mg). Each compound was identified by comparing 95 its 1 H, 13 ImmunoStar LD (Wako Pure Chemical Industries, Osaka, Japan). The luminescence 212 intensity was quantified using ImageJ. as beta, 10 while in another reference it was identified as alpha. 13 However, both of the 233 reported NMR spectra and optical rotations were the same as those obtained for 234 compound 2 here, indicating that one of the previous stereochemistry assignments is 235 incorrect. Therefore, through this study, we re-examined and clarified the 236 stereochemistry of the epoxide. 237 Measurement of the NOESY spectra of this compound showed a correlation 238 between H-12 and H a -21, which was considered as an evidence of the α-epoxide in the 239 previous study. 13 However, the distance between those two hydrogen atoms was similar 240 between the α and β-epoxide structure models (see Supporting information). 241 Therefore, the observed NOESY correlation was considered insufficient evidence to 242 determine its stereochemistry. To examine and verify its stereochemistry, compound 2 243 was then acetylated to obtain di-O-acetyl product 4 and the NOESY experiment was 244 performed using 4. In compound 4, a NOESY correlation was observed between H b -21 245 and AcO-15. Thus, the stereochemistry of the epoxide was confirmed to be beta, which 246 is a biosynthetically reasonable configuration if the epoxide 2 is hydrolyzed to produce 247 its dihydroxy derivative 3 in planta. In light of this finding, we need to consider that The three isolated compounds were evaluated for anti-obesity activities; 256 enhancement of glycerol release and reduction of lipid accumulation. Compounds 1 and 257 2 showed concentration-dependent activity in the glycerol release enhancement assay, 258 and reduced the lipid accumulation without cytotoxic effects (Fig. 2) . The EC 50 value 16 259 for the glycerol release enhancement was 14.6 µM for 1, while 2 had a lower EC 50 (8.6 260 µM). The stronger bioactive effects of 2 indicates the importance of the epoxide group 261 in exerting its bioactivity. In contrast, the hydrolyzed derivative 3 did not show any 262 biological activity in either of the two assays ( Fig. 2A and 2B) , even at the highest 263 concentration tested (100 µM). The second possibility is that the epoxide group is the essential moiety for the 282 bioactivity. This would suggest that eurycomanone (1) is oxidized in the cells to form 283 its bioactive epoxide (2). However, there was no evidence for supporting this 284 hypothesis. Therefore, subsequent research on structure-activity relationship (SAR) of 285 these quassinoids is required to determine whether the epoxide group is the essential 286 part of the bioactivity. After evaluating their biological activities in reducing lipid accumulation and 18 290 enhancing lipolysis, molecular mechanism of the lipolytic activity of 1 and 2 was 291 further investigated. Since these compounds induced lipolysis in 3T3-L1 cells, the 292 signaling molecules related to the activation of hormone-sensitive lipase (HSL) were 293 predicted to involve. 19 Initially, we tested the two well-known lipolytic signaling 294 molecules; protein-kinase A (PKA) and extracellular signal-regulated kinase (ERK), 20 295 by co-incubating 1 and 2 with the respective specific inhibitors (Fig. 3A and 3B ). To further investigate the target of 1 and 2, β3-adrenergic receptor, the major 315 upstream target of PKA, was examined. 21 Compounds 1 and 2 were co-incubated with 316 propranolol, an antagonist of β3-adrenergic receptor, but the antagonist had no effect 317 on the lipolytic activity of the both compounds (Fig. 3C ). Based on these findings, it is 318 conclusively evident that 1 and 2 induce their lipolytic effects through the direct 319 activation of PKA. Lipolytic activity of 1 and 2 might also work through the other 320 upstream related signaling proteins, but not through the β3-adrenergic receptor located 321 at the cell membrane ( Fig. 5 ). 
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